HomeREGULATORY
REGULATORY

MHLW Advisory Panel to Review Otsuka’s Schizophrenia Med Brexpiprazole on Dec. 4
(Nov.22.2017)

A key advisory committee of the Ministry of Health, Labor and Welfare (MHLW) will discuss on December 4 whether to recommend approval for Otsuka Pharmaceutical’s schizophrenia treatment brexpiprazole. Otsuka positions the drug as a successor to its antipsychotic agent Abilify (aripiprazole) ...
(LOG IN FOR FULL STORY)